Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 5Completed 5Terminated 4Active not recruiting 4Withdrawn 2Recruiting 1Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 11INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 53Colorectal Neoplasms 52Neoplasms 40Advanced Solid Tumors 34Prostatic Neoplasms 31Multiple Myeloma 31Ovarian Neoplasms 28Neoplasm Metastasis 28Recurrence 27Lung Neoplasms 27Carcinoma, Hepatocellular 27Pancreatic Neoplasms 26Advanced Solid Tumor 22Small Cell Lung Carcinoma 20Leukemia, Myeloid, Acute 20Melanoma 18Endometrial Neoplasms 18Triple Negative Breast Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Lymphoma, Follicular 14Stomach Neoplasms 13Lymphoma, B-Cell 13Glioma 13Glioblastoma 13Uterine Cervical Neoplasms 12Lymphoma 11Head and Neck Neoplasms 11Solid Tumor 10Myasthenia Gravis 9

Interventions

sugemalimab 1pegaspargase 1Oxaliplatin 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Lymphoma, Extranodal NK-T-Cell × Clear all
NCT05700448 2026-05-27

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

CStone Pharmaceuticals

Phase 3 Not yet recruiting
150 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡